Calyx and Invicro have launched under a new corporate identity: Perceptive.
 
The new name reflects the organization’s increased strengths and capabilities, as they consolidate their place as a leader in the provision of discovery, imaging, and eClinical solutions and services.
 
Expanding on their combined 50+ year history, Perceptive provides specialist support to global pharmaceutical, biotech, and clinical research organizations, spanning the complete R&D lifecycle, from discovery and preclinical through clinical development to post marketing. Perceptive’s offerings include imaging biomarkers and core lab services, as well as innovative technologies in randomization and trial supply management (RTSM), analytics and software.
 
“Today marks a major milestone for Perceptive, as we advance our mission to serve science. We are committed to delivering the diligence, drive, and innovation today that will enable the global clinical research community to realize tomorrow’s new therapies,” said Perceptive CEO, David Herron. “We’re honored to be part of the global healthcare solution by providing unmatched scientific and technological expertise, global operational experience, and end-to-end solutions that ensure confident R&D decision-making.​”
 
Guided by values of customer-centricity, quality and accountability, and with global reach across the US, Europe and Asia, Perceptive will support researchers across three key areas:
 

• Perceptive Discovery – identifying the most promising candidate compounds and minimizing risk on the path to clinical success with a collaborative approach to premier preclinical and first-in-human imaging services
• Perceptive eClinical – optimizing patient and clinical supply management through the alliance of expertise, innovation and agility
• Perceptive Imaging – advancing novel therapies with scientific, regulatory and global operational expertise that drives efficient and high-quality data across small and large-scale clinical trials.

 
Perceptive’s expertise is reflected in the support of almost 12,000 clinical research trials and 800+ approvals to date, across all clinical phases and therapeutic areas, with concentrated expertise in oncology and neuroscience. Moving forward under its new name, Perceptive will continue to serve science by delivering clarity and consistency for clinical trials worldwide on delivery, speed and results.